Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $264.64 and traded as high as $282.06. Genmab A/S shares last traded at $272.99, with a volume of 579 shares trading hands.
Genmab A/S Trading Down 0.7 %
The firm’s fifty day moving average is $264.64 and its 200 day moving average is $278.49. The company has a market cap of $17.85 billion, a PE ratio of 22.60 and a beta of 1.05.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported $3.13 EPS for the quarter. The business had revenue of $779.50 million during the quarter. Genmab A/S had a net margin of 29.06% and a return on equity of 20.60%.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Small Cap Stocks That Insiders Are Buying
- What is a Low P/E Ratio and What Does it Tell Investors?
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
